Incidence rate
(per 100 person-years)		   Hazard ratio
(95% CI)		 P value
NOAC Reference
5 mg apixaban vs 150 mg dabigatran (reference) n = 5904 n = 5904
 
    
Stroke/SE* 1.3 1.3
 
 0.92 (0.55-1.52) .733
Major bleeding† 3.0 3.7
 
 0.77 (0.59-1.00) .052
5 mg apixaban vs 20 mg rivaroxaban (reference) n = 16,553 n = 16,553
 
    
Stroke/SE* 1.2 1.2
 
 0.93 (0.74-1.17) .524
Major bleeding† 3.3 5.7
 
 0.53 (0.47-0.60) <.001
150 mg dabigatran vs 20 mg rivaroxaban (reference) n = 6169 n = 6169
 
    
Stroke/SE* 1.3 1.1
 
 1.18 (0.85-1.65) .321
Major bleeding† 3.6 4.9
 
 0.74 (0.61-0.89) .001
0.0
0.5
1.0
1.5
2.0
Favors comparator
Favors reference

No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs
versus DOACs.

Appearance of plotted data may be altered when zoom greater than 150% is applied;
refer to values in tables for context when view is zoomed.

1|2|3|4|5